New drug targets stomach cancer protein, shows promise in early trial
NCT ID NCT03505320
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests a drug called zolbetuximab for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). The drug attaches to this protein and helps the immune system attack the tumor. Participants receive zolbetuximab alone or combined with chemotherapy or immunotherapy. The main goal is to see how well the drug controls tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mass General / North Shore Can
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Site FR33001
Brest, France
-
Site FR33002
Poitiers, New Aquitaine, 86021, France
-
Site FR33003
Pessac, New Aquitaine, 33604, France
-
Site FR33004
Paris, 75015, France
-
Site IT39002
Naples, Italy
-
Site IT39003
Pisa, Italy
-
Site IT39004
Padova, Italy
-
Site IT39005
Milan, Italy
-
Site JP81001
Chiba, Japan
-
Site JP81002
Tokyo, Japan
-
Site JP81003
Tokyo, Japan
-
Site KR82001
Seoul, South Korea
-
Site KR82002
Seongnam-si, South Korea
-
Site TW88601
Taichung, Taiwan
-
Site TW88602
Tainan, 70403, Taiwan
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
UCLA Medical Center
Santa Monica, California, 90404, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.